KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Beginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in CashDeferred TaxesDepreciation & Amortization (CF)DivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Teva Pharmaceutical Industries (TEVA) Change in Account Payables: 2009-2016

Historic Change in Account Payables for Teva Pharmaceutical Industries (TEVA) over the last 7 years, with Sep 2016 value amounting to $5.0 billion.

  • Teva Pharmaceutical Industries' Change in Account Payables rose 67.11% to $5.0 billion in Q3 2016 from the same period last year, while for Sep 2016 it was $15.9 billion, marking a year-over-year increase of 31.14%. This contributed to the annual value of $3.6 billion for FY2015, which is 13.34% up from last year.
  • Latest data reveals that Teva Pharmaceutical Industries reported Change in Account Payables of $5.0 billion as of Q3 2016, which was up 28.48% from $3.9 billion recorded in Q2 2016.
  • In the past 5 years, Teva Pharmaceutical Industries' Change in Account Payables ranged from a high of $5.0 billion in Q3 2016 and a low of $2.9 billion during Q3 2014.
  • In the last 3 years, Teva Pharmaceutical Industries' Change in Account Payables had a median value of $3.1 billion in 2014 and averaged $3.4 billion.
  • In the last 5 years, Teva Pharmaceutical Industries' Change in Account Payables dropped by 5.49% in 2012 and then spiked by 67.11% in 2016.
  • Over the past 5 years, Teva Pharmaceutical Industries' Change in Account Payables (Quarterly) stood at $3.4 billion in 2012, then fell by 1.75% to $3.3 billion in 2013, then fell by 4.40% to $3.2 billion in 2014, then climbed by 13.34% to $3.6 billion in 2015, then skyrocketed by 67.11% to $5.0 billion in 2016.
  • Its Change in Account Payables stands at $5.0 billion for Q3 2016, versus $3.9 billion for Q2 2016 and $3.5 billion for Q1 2016.